News & Events about Eagle Pharmaceuticals Inc.
Globe Newswire
6 months ago
WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President...
WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delawares decision that Eagles vasopressin product ...
BNP Paribas Arbitrage SA lessened its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 45.8% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 6,397 shares of the specialty pharmaceutical companys stock after selling 5,396 ...
Principal Financial Group Inc. decreased its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) by 10.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 87,897 shares of the specialty pharmaceutical company&#...
Equities analysts forecast that Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX Get Rating) will report earnings per share of $3.91 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Eagle Pharmaceuticals earnings, with estimates ...